Bupropion Hydrochloride Tablet, Film Coated
Product Images NDC 60505-0157

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Bupropion Hydrochloride (NDC 60505-0157). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

100 mg 100 Tablets

100 mg 100 Tablets
Each tablet of BuPROPion Hydrochloride contains 100 mg of bupropion hydrochloride. It should be stored at a temperature of 20°C to 25°C, with excursions permitted from 15°C to 30°C. The tablets should be protected from moisture and dispensed in a tight, light-resistant container. The usual dosage and other information can be found in the package insert. Zyban® is a registered trademark of GlaxoSmithKline. The tablets come in a container of 100 tablets with an NDC number of 60505-0157-1. The manufacturer of the tablets is Apotex, located in Weston, Florida. The warning is not to use any other medicines that contain bupropion hydrochloride in combination with Zyban®. The pharmacist is instructed to dispense with the medication guide available.*
FDA Label Image

75 mg 100 Tablets

75 mg 100 Tablets
Each tablet contains 75 mg bupropion hydrochloride. The tablets should be stored in a tight, light-resistant container, protected from moisture, and between 20°C to 25°C (68°F to 77°F) with excursions permitted from 15° to 30°C (5°F to 86°F). The usual dosage is stated in the package insert for BuPROPion Hydrochloride Tablets, USP, which is to be taken three times daily (after initial titration). Combining this medicine with Zyban or any other medication containing bupropion hydrochloride should be avoided. The tablets are manufactured by Apotecinc, Toronto, Ontario, Canada, and have been registered under the trademark name Zyban® by GlaxoSmithKline.*
FDA Label Image

Structure (Structure)

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.